Thursday, June 7, 2018

Treatment of HCV‐Associated Extrahepatic Manifestations in 2018

Clinical Liver Disease
© The American Association for the Study of Liver Diseases
Clinical Liver Disease (CLD) is an online learning resource of AASLD offering research articles with audio, video, webinars, and other interactive content designed for any physician or healthcare provider caring for a patient with liver disease.

Here is the latest June content: 

Reviews
Guest Edited by Elizabeth May, MD
When we look at the landscape in 2018, we find that the guidelines of the American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA) and European Association for the Study of the Liver (EASL) are in agreement that all patients with HCV infection should be treated with effective antiviral therapy.3, 4 Table 2 categorizes HCV‐associated EHMs according to severity.5 Treatment of patients with mild‐to‐moderate HCV‐associated EHMs is important because the first‐line treatment of HCV‐associated EHMs of mild‐to‐moderate severity is always initiation of DAA therapy. Patients with severe or life‐threatening EHMs of HCV should also receive the most appropriate DAAs.... 
Pages: 115-118
First Published:05 June 2018
Watch a video presentation of this article
Watch the interview with the author
Answer questions and earn CME
Abstract
Full text
PDF
References
Request permissions 

Pages: 105-110
First Published:05 June 2018
Watch a video presentation of this article
Watch the interview with the author
Abstract
Full text
PDF
References
Request permissions

Free Access
Hepatic fibrosis: Avenues of investigation and clinical implications

Jessica E.S. Shay M.D.
James P. Hamilton M.D., Ph.D.
Pages: 111-114
First Published:05 June 2018
Watch a video presentation of this article
Answer questions and earn CME
Abstract
Full text
PDF
References

ALF Debate 2017
Guest Edited by Lisa B. VanWagner, MD
Free Access
PRO (“The Window Is Open”): In patients with cirrhosis with prior variceal hemorrhage and ascites, the clinical benefits of nonselective beta‐blockers outweigh the risks and should be prescribed

Danielle Tholey M.D.
Nitzan Roth M.D., Ph.D.
Thomas Schiano M.D.
Pages: 119-122
First Published:05 June 2018
Watch a video presentation of this article
Abstract
Full text
PDF
References
Request permissions

Free Access
CON (“The window is closed”): In patients with cirrhosis with ascites, the clinical risks of nonselective beta‐blocker outweigh the benefits and should NOT be prescribed

Ariel W. Aday M.D.
Nicole E. Rich M.D.
Arjmand R. Mufti M.D.
Shannan R. Tujios M.D.
Pages: 123-127
First Published:05 June 2018
Watch a video presentation of this article
Abstract
Full text
PDF
References
Request permissions

Radiology in Liver Disease

Megan G. Lubner, MD
Free Access
Imaging of abnormal liver function tests

Saivenkat H. Vagvala D.O.
Stacy D. O'Connor M.D., M.P.H.
Pages: 128-134
First Published:05 June 2018
Watch a video presentation of this article
Watch the interview with the author
Abstract
Full text
PDF
References

No comments:

Post a Comment